Sarepta Therapeutics Inc Q1 2022 Earnings Call Summary - Thomson StreetEvents

Sarepta Therapeutics Inc Q1 2022 Earnings Call Summary

Sarepta Therapeutics Inc Q1 2022 Earnings Call Summary - Thomson StreetEvents
Sarepta Therapeutics Inc Q1 2022 Earnings Call Summary
Published May 04, 2022
17 pages (9470 words) — Published May 04, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of SRPT.OQ earnings conference call or presentation 4-May-22 8:30pm GMT

  
Brief Excerpt:

...A. Highlights: SRPT enjoyed yet another straight qtr. of strong revenue growth for three approved therapy - EXONDYS 51, VYONDYS 53 and AMONDYS 45, achieving total revenue of $210.8m and net product revenues of nearly $190m. 1. Net product revenue performance represents 50% YoverY. a. b. Led by AMONDYS each of three therapies contributed to outsized growth over same qtr. prior year. 2. Achieved over five years of sustained growth with compounded annual growth rate of nearly 40%. Done that without single price increase and by pricing all of therapies [imperatively]. a. 3. Co.'s consistently strong performance comes from serving patient community. It reflects value that these therapies bring to individuals living with Duchenne. a. 4. Based on performance to date, can confirm prior guidance of net product revenue of over $800m for full year 2022, translating into product revenue growth of over 30% over 2021. 5. In 1Q, continued to advance large pipeline of potentially life-enhancing therapies...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Sarepta Therapeutics Inc
Ticker
SRPT.OQ
Time
8:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on all the progress. Doug, maybe you could just give us a quick update on when you expect to meet with FDA regarding the path forward and filing strategy for 9001. It seems that hasn't happened yet. And then just quickly on your competitor, Pfizer. They're about to initiate trials in the U.S. And so I just wanted your updated thinking on how you view them as a competitor from a timing and, I guess, clinical profile perspective. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 04, 2022 / 8:30PM, SRPT.OQ - Q1 2022 Sarepta Therapeutics Inc Earnings Call

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Want to ask one around longer-term plans of the company. So if you see this cannibalization around gene therapy and are able to solve the problem for the 15% or so of patients with preexisting neutralizing antibodies, given the success you've seen, would you consider utilizing the PPMO platform for other potential indications or areas beyond DMD?

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : So my question is on the LGMD program. And sorry if I missed -- if you had provided an update, but what about the next step and also the time line? Are you still working on the CMC issues? And so do you have a plan to move the 2E program forward? Or do you think given the prevalence that a basket study will make more sense and you're trying to align with the FDA on that plan, please?

Question: Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst : Just wondering what the status of the ESSENCE confirmatory trial enrollment was. If I look at the clinical trial, it seems that enrollment should be done soon.

Table Of Contents

Sarepta Therapeutics Inc to Provides Update on SRP-5051 for the Treatment of Duchenne Summary – 2022-06-23 – US$ 54.00 – Edited Brief of SRPT.OQ conference call or presentation 23-Jun-22 8:15pm GMT

Sarepta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript – 2022-06-14 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 14-Jun-22 5:00pm GMT

Sarepta Therapeutics Inc Annual Shareholders Meeting Transcript – 2022-06-02 – US$ 54.00 – Edited Transcript of SRPT.OQ shareholder or annual meeting 2-Jun-22 1:00pm GMT

Sarepta Therapeutics Inc at Bank of America Healthcare Conference Transcript – 2022-05-11 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 11-May-22 4:20pm GMT

Sarepta Therapeutics Inc Q1 2022 Earnings Call Transcript – 2022-05-04 – US$ 54.00 – Edited Transcript of SRPT.OQ earnings conference call or presentation 4-May-22 8:30pm GMT

Sarepta Therapeutics Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript – 2022-03-31 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 31-Mar-22 4:00pm GMT

Sarepta Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript – 2022-03-15 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 15-Mar-22 7:20pm GMT

Sarepta Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript – 2022-03-09 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 9-Mar-22 7:10pm GMT

Sarepta Therapeutics Inc Q4 2021 Earnings Call Summary – 2022-03-01 – US$ 54.00 – Edited Brief of SRPT.OQ earnings conference call or presentation 1-Mar-22 9:30pm GMT

Sarepta Therapeutics Inc Q4 2021 Earnings Call Transcript – 2022-03-01 – US$ 54.00 – Edited Transcript of SRPT.OQ earnings conference call or presentation 1-Mar-22 9:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Sarepta Therapeutics Inc Q1 2022 Earnings Call Summary" May 04, 2022. Alacra Store. May 18, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2022-Sarepta-Therapeutics-Inc-Earnings-Call-B15192774>
  
APA:
Thomson StreetEvents. (2022). Sarepta Therapeutics Inc Q1 2022 Earnings Call Summary May 04, 2022. New York, NY: Alacra Store. Retrieved May 18, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2022-Sarepta-Therapeutics-Inc-Earnings-Call-B15192774>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.